Mehran Yusuf

Dr. Mehran Yusuf


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
GMGrant McKenzie
Grant McKenzie
JGJeremy Gaskins
Jeremy Gaskins
ARAbbas Rattani
Abbas Rattani
AOAlexandria Oliver
Alexandria Oliver
WSWilliam Southall
William Southall
SWShiao Woo
Shiao Woo

15 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ARAbbas Rattani
Abbas Rattani
JGJeremy Gaskins
Jeremy Gaskins
GMGrant McKenzie
Grant McKenzie
VSVirginia Kate Scharf
Virginia Kate Scharf
KBKristy Broman
Kristy Broman
MYMehran Yusuf
Mehran Yusuf
Merkel Cell Carcinoma (MCC) is a rare cancer most commonly affecting White patients; less is known for Black patients. We aim to report presentation, treatment, and quality of registry data by race with a secondary endpoint of overall survival. We conducted a retrospective cohort analysis between 2006–2017 via the National Cancer Database of Black and White MCC patients with and without known staging information. Multivariable logistic, proportional odds logistic, and baseline category logistic regression models were used for our primary endpoint. Multivariable Cox regression was used to interrogate overall survival. Multiple imputation was used to mitigate missing data bias. 34,503 patients with MCC were included (2566 Black patients). Black patients were younger (median age 52 vs. 72, p < 0.0001), had higher rates of immunosuppression (28% vs. 14%, p = 0.0062), and were more likely to be diagnosed at a higher stage (proportional OR = 1.41, 95% CI 1.25–1.59). No differences were noted by race across receipt of definitive resection (DR), though Black patients did have longer time from diagnosis to DR. Black patients were less likely to receive adjuvant radiation. Black patients were more likely to have missing cancer stage (OR = 1.69, CI 1.52–1.88). Black patients had decreased adjusted risk of mortality (HR 0.73, 0.65–0.81). Given the importance of registry analyses for rare cancers, efforts are needed to ensure complete data coding. Paramount to ensuring equitable access to optimal care for all is the recognition that MCC can occur in Black patients.

1 December 2024 in Applied Radiation Oncology
Verified
Journal Article
Closed access
MBMichayla B. Brown
Michayla B. Brown
MYMehran Yusuf
Mehran Yusuf
JHJoseph M. Harms
Joseph M. Harms
JPJoel A. Pogue
Joel A. Pogue
DSDennis N. Stanley
Dennis N. Stanley
AMAndrew McDonald
Andrew McDonald
Testicular cancers are a common etiology for painless testicular masses occurring in young adult males between the ages of 20 and 34, with 50% diagnosed as seminomas. Seminomas are a malignant germ-cell tumor most commonly confined to the testicles with less frequent de novo involvement of structures outside of the seminiferous tubules. Radiation therapy (RT) has historically been indicated for patients with stage 1-2 seminoma, but its use is declining due to increased uptake of surveillance and modern chemotherapy. However, seminoma is a radiosensitive tumor, and RT may play a role in select cases. This case report describes a nontypical presentation of a large IIC retroperitoneal seminoma measuring 15 cm in an older patient who was a suboptimal candidate for chemotherapy. He was treated with an online adaptive external-beam radiation platform, leading to a significant reduction in body and bowel dose compared with standard-of-care radiation treatment. Clinical regression of tumor was achieved while sparing exposure to significant volumes of bowel and healthy pelvic tissue. The patient had an uneventful recovery and showed no signs of radiation dermatitis or gastrointestinal toxicity.